 |
selective deacylglycerol acyltransferase 1 inhibitor |
|---|---|
| Trade Name | |
| Orphan Indication | Hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2011-03-28 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 |
